07:57 AM EDT, 08/18/2025 (MT Newswires) -- Unicycive Therapeutics ( UNCY ) said Monday it received a US patent for UNI-494 to treat chronic kidney disease, following an earlier patent covering acute kidney injury.

The drug has completed a phase 1 trial in healthy volunteers and holds orphan drug designation for preventing delayed graft function in kidney transplant patients, the company said.

The new patent expands its intellectual property portfolio and supports potential partnerships and future development, Unicycive said.